Marketing


  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

    Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.

    By Amy Baxter • May 22, 2024
  • A vial of Eisai and Biogen's Alzheimer's disease drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai sets new revenue target for Alzheimer’s drug Leqembi

    The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies analysts.

    By May 15, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Biosimilars are gaining ground. The IRA could push them further next year.

    As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

    By Amy Baxter • May 13, 2024
  • Two prescription drug cartons are seen stacked on top of each other, bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo sees Wegovy sales dip on lower price, tight supply

    First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

    By May 2, 2024
  • A chromatic Pfizer sign hangs on a building façade
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

    Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.

    By May 1, 2024
  • Deira Ward (L) and Lisa Bates (R) work at a computer near a large PCR analysis machine at a Quest Diagnostics testing lab in Indianapolis, Indiana. The lab is capable of processing up to 3700 tests pe
    Image attribution tooltip
    Jon Cherry via Getty Images
    Image attribution tooltip

    FDA defends lab test rule, as critics fear industry upheaval

    The new policy aims to ensure important diagnostics remain available to patients, but some experts caution the increased regulatory burden could slow access to testing.

    By Susan Kelly • April 30, 2024
  • Close up of a droplet being dropped into a test tube
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip

    FDA finalizes lab developed test rule over industry opposition

    Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.

    By Susan Kelly • April 29, 2024
  • Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    AbbVie tries to reassure investors on Humira biosimilar threat

    Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

    By April 26, 2024
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen to invest more in launch of Alzheimer’s drug Leqembi

    Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.

    By April 24, 2024
  • Anne Wojcicki speaking event
    Image attribution tooltip
    Brad Barket via Getty Images
    Image attribution tooltip

    23andMe CEO plans to take company private

    Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

    By Elise Reuter • April 18, 2024
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Stelara biosimilar from Alvotech, Teva approved by FDA

    The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

    By Kristin Jensen • April 17, 2024
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche reports survival data for new dual-acting lymphoma drug

    The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

    By April 15, 2024
  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    European regulator concludes no suicide link to obesity drugs

    The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

    By April 12, 2024
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US sues Regeneron, alleging false price reporting on Eylea

    The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

    By Kristin Jensen • April 11, 2024
  • FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

    The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers. 

    By March 25, 2024
  • Doctor hands texting on a smart phone
    Image attribution tooltip

    shutterstock.com/VAlekStudio

    Image attribution tooltip
    Sponsored by Veeva

    Give HCPs a proactive way to reach your field team: Add inbound

    HCPs today want inbound channels for help when they need it. See how you can meet their preferences.

    By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024
  • The East facade of the Capitol Building in Washington DC.
    Image attribution tooltip
    dkfielding via Getty Images
    Image attribution tooltip

    BIO changes stance, backs bill to limit China’s role in US biotech

    Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

    By March 14, 2024
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    After surprise trial failure, ALS doctors brace for one less treatment option

    Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.

    By Updated April 4, 2024
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    Novavax agrees to pay Gavi in settlement over COVID vaccine contract

    Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.

    By Kristin Jensen • Feb. 22, 2024
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Ipsen drug approved by FDA for early pancreatic cancer

    The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

    By Feb. 14, 2024
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen has a fuzzy line of sight on prized Alzheimer’s drug

    CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.

    By Feb. 13, 2024
  • Compass on rocks with a dark sky
    Image attribution tooltip

    stock.adobe.com//ergregory

    Image attribution tooltip
    Sponsored by Alexander Group

    Chart a course for sustainable growth

    Explore how companies are optimizing efficiency, enhancing customer experiences and embracing AI.

    Feb. 12, 2024
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai falls behind on Leqembi patient goal

    The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.

    By Feb. 6, 2024
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen quits Aduhelm, handing back rights to original developer

    The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

    By Jan. 31, 2024
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA orders new cancer warnings for CAR-T therapies

    The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.

    By Updated Jan. 24, 2024